[Oncolytic parvoviruses. A new approaches for cancer therapy]

Area of Science:

• Oncolytic virotherapy
• Cancer immunology
• Molecular virology

Context:

• Parvoviruses, including parvovirus H-1 (H-1PV), exhibit selective oncolytic properties.
• These viruses can induce anti-tumor immunity, aiding in tumor cell elimination.
• Parvoviral proteins NS1 and 11 kDa are implicated in inducing apoptosis in cancer cells.

Purpose:

• To explore the potential of parvoviruses as oncolytic agents for cancer therapy.
• To investigate the mechanisms of anti-tumor activity, including apoptosis induction and immune response.
• To evaluate the efficacy of parvovirus-based vectors in preclinical models and clinical trials.

Summary:

• Parvoviruses selectively infect and lyse cancer cells, simultaneously triggering an immune response against tumors.
• Antitumor effects are mediated by parvoviral proteins inducing apoptosis and by the host's immune system.
• Parvovirus-based vectors have shown success in animal models for various cancers and are being tested in human clinical trials.

Impact:

• Parvovirus-based therapies offer a promising avenue for gene therapy in oncological and genetic diseases.
• The development of oncolytic preparations like ParvOryx, based on H-1PV, is advancing cancer treatment strategies.
• Ongoing clinical trials for glioblastoma multiforme indicate the therapeutic potential of H-1PV in human patients.